UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q2 2022 | 2022-11-07 | Future report Set alerts | |
| Q1 2022 | 2022-08-10 | 0.58 | 0.58 |
| Q4 2021 | 2022-05-10 | 0.65 | 0.65 |
| Q3 2021 | 2022-02-08 | 0.84 | 0.84 |
| Q2 2021 | 2021-11-09 | 0.60 | 0.60 |
| Q1 2021 | 2021-08-11 | 0.50 | 0.50 |
| Q4 2020 | 2021-05-13 | 0.46 | 0.46 |
| Q3 2020 | 2021-02-02 | 0.81 | 0.81 |
| Q2 2020 | 2020-11-04 | 0.00 | 0.00 |
| Q1 2020 | 2020-08-04 | 0.46 | 0.21 |
| 2016-05-16 | Upgrade | Goldman Sachs | Sell to Neutral | $29.00 |
| 2016-05-16 | Upgrade | Goldman Sachs Group Inc. | Sell to Neutral | $29.00 |
| 2016-05-15 | Reiterated Rating | BTIG Research | Hold | |
| 2016-05-12 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-05-11 | Lower Price Target | Benchmark Co. | Hold | $35.00 to $28.00 |
| 2016-05-03 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-05-03 | Lower Price Target | Barrington Research | Outperform | $40.00 to $32.00 |
| 2016-04-19 | Reiterated Rating | BTIG Research | Hold | |
| 2016-03-12 | Reiterated Rating | BTIG Research | Hold | |
| 2016-02-02 | Boost Price Target | Jefferies Group | Buy | $38.00 to $40.00 |
| 2016-02-02 | Boost Price Target | Barrington Research | Outperform | $38.00 to $40.00 |
| 2016-02-02 | Reiterated Rating | William Blair | Market Perform | |
| 2016-02-01 | Reiterated Rating | BTIG Research | Neutral | |
| 2016-01-06 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-12-14 | Initiated Coverage | BTIG Research | Neutral | |
| 2015-11-23 | Downgrade | Raymond James | Market Perform to Underperform | |
| 2015-11-23 | Downgrade | Raymond James Financial Inc. | Market Perform to Underperform | |
| 2015-11-05 | Lower Price Target | Benchmark Co. | Hold | $42.00 to $35.00 |
| 2015-10-06 | Lower Price Target | Barrington Research | Outperform | $43.00 to $38.00 |
| 2015-10-06 | Lower Price Target | Jefferies Group | Buy | $47.00 to $38.00 |
| 2015-07-28 | Lower Price Target | Jefferies Group | Buy | $48.00 to $47.00 |
| 2015-07-28 | Upgrade | Barrington Research | Market Perform to Outperform | $43.00 |
| 2015-04-28 | Boost Price Target | Benchmark Co. | Hold | $39.00 to $42.00 |
| 2015-04-28 | Downgrade | Barrington Research | Outperform to Market Perform | $44.00 |
| 2015-04-28 | Boost Price Target | Jefferies Group | Buy to Buy | $45.00 to $48.00 |
| 2015-02-23 | Set Price Target | Morgan Stanley | Hold | $45.00 |
| 2015-01-05 | Boost Price Target | Jefferies Group | Buy | $41.00 to $45.00 |
| 2014-11-20 | Initiated Coverage | Barrington Research | Outperform | $46.00 |
| 2014-07-31 | Boost Price Target | Jefferies Group | Buy | $38.00 to $41.00 |
| 2014-05-21 | Reiterated Rating | Jefferies Group | Buy | $36.00 to $38.00 |
| 2014-04-29 | Lower Price Target | Jefferies Group | Buy | $38.00 to $36.00 |
| 2014-03-25 | Lower Price Target | Benchmark Co. | $46.00 to $41.00 | |
| 2014-03-25 | Lower Price Target | Jefferies Group | $45.00 to $38.00 | |
| 2014-03-24 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2014-03-24 | Downgrade | William Blair | Outperform to Market Perform | |
| 2014-03-07 | Upgrade | Sidoti | Neutral to Buy | |
| 2014-01-28 | Lower Price Target | Jefferies Group | $48.00 to $45.00 | |
| 2013-12-31 | Downgrade | The Benchmark Company | Buy to Hold | $49 to $46 |
| 2013-12-31 | Downgrade | Benchmark Co. | Buy to Hold | $49.00 to $46.00 |
| 2013-12-17 | Downgrade | Goldman Sachs | Neutral to Sell | $40.00 to $39.00 |
| 2013-11-26 | Initiated Coverage | Jefferies Group | Buy | $48.00 |
| 2013-06-05 | Initiated | William Blair | Outperform | |
| 2012-09-13 | Initiated | The Benchmark Company | Buy | $89 |
| 2011-08-03 | Upgrade | Barrington Research | Mkt Perform to Outperform | $70 |
| 2010-01-06 | Initiated | Barrington Research | Outperform | $67 |
| 2009-02-03 | Reiterated | Maxim Group | Buy | $72 to $75 |
| 2009-01-28 | Initiated | Maxim Group | Buy | $72 |
| 2008-09-03 | Upgrade | Avondale | Mkt Perform to Mkt Outperform | $72 |
| 2008-02-01 | Reiterated | Dawson James | Buy | $55 to $65 |
| 2007-02-22 | Initiated | Susquehanna Financial | Positive |
| 2016-05-16 | Upgrade | Goldman Sachs | Sell to Neutral | $29.00 |
| 2016-05-16 | Upgrade | Goldman Sachs Group Inc. | Sell to Neutral | $29.00 |
| 2016-05-15 | Reiterated Rating | BTIG Research | Hold | |
| 2016-05-12 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-05-11 | Lower Price Target | Benchmark Co. | Hold | $35.00 to $28.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In HAE 215 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Capital Research Global Investors | 6.29M |
| BlackRock Inc. | 5.54M |
| WELLINGTON MANAGEMENT CO LLP | 5.37M |
| Vanguard Group, Inc | 5.20M |
| BlackRock Fund Advisors | 4.14M |
| Neuberger Berman Group LLC | 3.89M |
| STATE STREET CORP | 1.70M |
| FRANKLIN RESOURCES INC | 1.35M |
| BlackRock Institutional Trust Company, N.A. | 1.33M |
| Fisher Asset Management, LLC | 1.25M |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 0.91M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.89M |
| ROYCE & ASSOCIATES LLC | 0.87M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.76M |
| DIMENSIONAL FUND ADVISORS LP | 0.72M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| CONCANNON BRIAN President & CEO | 0.29% (147040) | CNMD / HAE / |
| Simon, Christopher President & CEO | 0.26% (131383) | HAE / |
| LINDOP CHRISTOPHER J CFO & EVP Business Development | 0.11% (56743) | HAE / PRXL / QTNT / |
| GELBMAN RONALD G | 0.11% (54017) | HAE / |
| ALLEN PETER M President, Global Plasma | 0.07% (34102) | HAE / |
| GRANADILLO PEDRO P | 0.06% (32381) | DNDN / HAE / NPSP / RCKT / |
| White Jonathan Chief Scientific and Technogy | 0.06% (30507) | HAE / |
| Jesse Sandra Chief Legal Officer | 0.06% (29861) | HAE / |
| MEELIA RICHARD J | 0.05% (26911) | HAE / LPTN / |
| KROLL MARK W | 0.05% (26763) | HAE / TASR / |
| FOOTE SUSAN BARTLETT | 0.04% (20740) | HAE / |
| HANLON SUSAN M VP Finance | 0.04% (20464) | HAE / |
| Selman Byron President, Global Markets | 0.04% (20148) | HAE / |
| Ryding Neil 122-62-507 EVP, Global Manufacturing | 0.04% (19676) | HAE / |
| MERRIMAN RONALD | 0.03% (17807) | AYR / HAE / O / PNR / |
| FORISH JOSEPH J VP, Human Resources | 0.03% (17279) | HAE / |
| Dockendorff Charles J | 0.03% (17184) | BSX / COV / HAE / HOLX / |
| Davies Kent J President, Global Markets | 0.03% (16891) | HAE / |
| Burns Brian R EVP, Global QA/RA | 0.03% (16235) | HAE / |
| Burke Willaim P EVP, Chief Financial Officer | 0.03% (14034) | HAE / |
| Fusco David EVP, Global Human Resources | 0.03% (13553) | HAE / |
| Helsel Dave EVP, Global Manufacturing | 0.03% (13216) | HAE / |
| Kelly Michael P President, Global Markets | 0.02% (10987) | HAE / |
| Basil Michelle L EVP and General Counsel | 0.02% (10786) | HAE / |
| BEST LAWRENCE C | 0.02% (10001) | HAE / MYGN / |
| Black Paul | 0.02% (8981) | HAE / MDRX / |
| BURZIK CATHERINE M | 0.02% (8599) | BDX / HAE / |
| McDaniel Kathleen EVP Global Human Resources | 0.01% (5013) | HAE / |
| Scanlan Jacqueline SVP, Global Human Resources | 0.01% (4524) | HAE / |
| Goldstein Dan Chief Accounting Officer | 0.01% (3681) | HAE / |
| ABERNATHY ROBERT E | 0.01% (2909) | HAE / KMB / POL / RSH / |
UM